For research use only. Not for therapeutic Use.
Neuropeptide W-23 (human) (NPW-23), the active form of Neuropeptide W, is an endogenous agonist of NPBW1 (GPR7) and NPBW2 (GPR8)[1].
Neuropeptide W-23 (human) (NPW-23) increases the ICa,L in transfected human embryonic kidney 293 cells and VSMCs via GPR7[1].
Neuropeptide W-23 (human) increases the expression of pan phospho-PKC, intracellular diacylglycerol level, and the second messenger catalyzed by PLC[1].
Neuropeptide W-23 (human) (NPW-23) (0.3-3.0 nM; intracerebroventricular injection; 2 μL) increases total behavioral activity, including locomotion and grooming in conscious rats[2].
Neuropeptide W-23 (human) (NPW-23) (2-8 nM; i.c.v.; 10 μL) shows anorexigenic effect in rats[3].
Catalog Number | I013085 |
CAS Number | 383415-79-0 |
Molecular Formula | C119H183N35O28S |
Purity | ≥95% |
Reference | [1]. Ji L, et al. Modulation of CaV1.2 calcium channel by neuropeptide W regulates vascular myogenic tone via G protein-coupled receptor 7. J Hypertens. 2015 Dec;33(12):2431-42. [2]. Pate AT, et al. Neuropeptide W increases mean arterial pressure as a result of behavioral arousal. Am J Physiol Regul Integr Comp Physiol. 2013 Oct 1;305(7):R804-10. [3]. Naso T, et al. Central neuropeptide W has anorexigenic effect in rats. J Anim Physiol Anim Nutr (Berl). 2014 Apr;98(2):228-34. |